ResMed (RMD) Reports In-Line Q4 EPS, Revenues Slightly Beat

ResMed (NYSE: RMD) reported Q4 EPS of $0.95, in-line with the analyst estimate of $0.95. Revenue for the quarter came in at $623.6 million versus the consensus estimate of $623.2 million.

• Revenue increased 12% to $623.6 million; up 10% on a constant currency basis
• Net income increased by 8%; non-GAAP net income up 24%
• GAAP diluted earnings per share of $0.76; non-GAAP diluted earnings per share of $0.95
• Operating cash flow of $129.4 million in the fourth quarter
• Quarterly dividend increased by 6% to $0.37 per share

“We closed out the year with strong performance across all aspects of our business, from solid top-line revenue growth - driven by geographically balanced results across our entire portfolio of offerings - to continued improvements in operating leverage, which has resulted in double-digit bottom-line growth,” said Mick Farrell, ResMed’s chief executive officer.

“We continue to advance our cloud-connected medical device strategy and are growing our cloud-based software-as-a-service business. Our clinical studies and research efforts are being recognized and the opportunity to increase awareness of sleep-related breathing disorders and improve patient quality of life is bigger than ever.”

Farrell concluded, “We believe we are well-positioned as we enter fiscal year 2019. We continue to innovate, we are improving our existing portfolio of products and offerings, and we have a robust pipeline to drive future growth.”

For earnings history and earnings-related data on ResMed (RMD) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• AMC Entertainment prices $200M stock offering to redeem senior notes
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits